292 related articles for article (PubMed ID: 18754430)
1. [Role of gonadotropin releasing hormone analogues for ovarian protection in systemic lupus erythematosus patients treated with cyclophosphamide].
Liang LQ; Qiu Q; Yang XY; Xu HS; Ye YJ; Zhan ZP; Lian F; Chen DY
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(15):1009-11. PubMed ID: 18754430
[TBL] [Abstract][Full Text] [Related]
2. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus.
Somers EC; Marder W; Christman GM; Ognenovski V; McCune WJ
Arthritis Rheum; 2005 Sep; 52(9):2761-7. PubMed ID: 16142702
[TBL] [Abstract][Full Text] [Related]
3. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study.
Manger K; Wildt L; Kalden JR; Manger B
Autoimmun Rev; 2006 Apr; 5(4):269-72. PubMed ID: 16697968
[TBL] [Abstract][Full Text] [Related]
4. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients.
Huong DL; Amoura Z; Duhaut P; Sbai A; Costedoat N; Wechsler B; Piette JC
J Rheumatol; 2002 Dec; 29(12):2571-6. PubMed ID: 12465154
[TBL] [Abstract][Full Text] [Related]
5. [Effects of gonadotropin releasing hormone analogues on chemotherapy-induced ovarian function damage in rats].
Peng P; Yang DZ; Zheng CY; Mo YQ; He YM; Zhang QX
Zhonghua Fu Chan Ke Za Zhi; 2007 Aug; 42(8):546-50. PubMed ID: 17983495
[TBL] [Abstract][Full Text] [Related]
6. Gonadotropin releasing hormone agonists may minimize cyclophosphamide associated gonadotoxicity in SLE and autoimmune diseases.
Blumenfeld Z; Mischari O; Schultz N; Boulman N; Balbir-Gurman A
Semin Arthritis Rheum; 2011 Dec; 41(3):346-52. PubMed ID: 21868068
[TBL] [Abstract][Full Text] [Related]
7. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy.
Blumenfeld Z; Shapiro D; Shteinberg M; Avivi I; Nahir M
Lupus; 2000; 9(6):401-5. PubMed ID: 10981642
[TBL] [Abstract][Full Text] [Related]
8. Gender difference: fertility preservation in young women but not in men exposed to gonadotoxic chemotherapy.
Blumenfeld Z
Minerva Endocrinol; 2007 Mar; 32(1):23-34. PubMed ID: 17353864
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy.
Mok CC; Lau CS; Wong RW
Arthritis Rheum; 1998 May; 41(5):831-7. PubMed ID: 9588734
[TBL] [Abstract][Full Text] [Related]
10. Should gonadotropin releasing hormone analogue be administered to prevent premature ovarian failure in young women with systemic lupus erythematosus on cyclophosphamide therapy?
Sinha R; Dionne JM
Arch Dis Child; 2008 May; 93(5):444-5. PubMed ID: 17908713
[No Abstract] [Full Text] [Related]
11. Ovarian failure and flares of systemic lupus erythematosus.
Mok CC; Wong RW; Lau CS
Arthritis Rheum; 1999 Jun; 42(6):1274-80. PubMed ID: 10366122
[TBL] [Abstract][Full Text] [Related]
12. Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma.
Blumenfeld Z; Avivi I; Eckman A; Epelbaum R; Rowe JM; Dann EJ
Fertil Steril; 2008 Jan; 89(1):166-73. PubMed ID: 17601603
[TBL] [Abstract][Full Text] [Related]
13. [Risk factors of ovarian failure in the patients with systemic lupus erythematosus receiving cyclophosphamide therapy].
Yang XY; Zhu X; Liang LQ; Zhan ZP; Ye YJ
Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):960-2. PubMed ID: 16061002
[TBL] [Abstract][Full Text] [Related]
14. Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus.
Ioannidis JP; Katsifis GE; Tzioufas AG; Moutsopoulos HM
J Rheumatol; 2002 Oct; 29(10):2129-35. PubMed ID: 12375322
[TBL] [Abstract][Full Text] [Related]
15. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus.
Petri M; Jones RJ; Brodsky RA
Arthritis Rheum; 2003 Jan; 48(1):166-73. PubMed ID: 12528116
[TBL] [Abstract][Full Text] [Related]
16. Effect of a gonadotropin-releasing hormone analog for ovarian function preservation after intravenous cyclophosphamide therapy in systemic lupus erythematosus patients: a retrospective inception cohort study.
Koga T; Umeda M; Endo Y; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Murakami N; Kitajima M; Kawakami A
Int J Rheum Dis; 2018 Jun; 21(6):1287-1292. PubMed ID: 29879312
[TBL] [Abstract][Full Text] [Related]
17. [Protective effect of estrogen against chemotherapy-induced ovarian damage in rats].
Han LP; He YL
Nan Fang Yi Ke Da Xue Xue Bao; 2009 May; 29(5):872-5. PubMed ID: 19460696
[TBL] [Abstract][Full Text] [Related]
18. Prevention of gonadal damage during cytotoxic therapy.
Blumenfeld Z; Haim N
Ann Med; 1997 Jun; 29(3):199-206. PubMed ID: 9240625
[TBL] [Abstract][Full Text] [Related]
19. Gonadal protection by a gonadotropin-releasing hormone agonist depot in young women with Hodgkin's disease undergoing chemotherapy.
Franke HR; Smit WM; Vermes I
Gynecol Endocrinol; 2005 May; 20(5):274-8. PubMed ID: 16019373
[TBL] [Abstract][Full Text] [Related]
20. Intravenous cyclophosphamide for lupus nephritis in Thai children.
Vachvanichsanong P; Dissaneewate P; Winn T
Scand J Rheumatol; 2004; 33(5):339-42. PubMed ID: 15513684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
